Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Oxford BioMedica Settle Litigation with Open Biosystems

NEW YORK (GenomeWeb News) – Sigma-Aldrich and Oxford BioMedica said today that they have settled their two-year-old litigation with Open Biosystems over patents covering lentiviral vector technology.
Sigma-Aldrich and Oxford agreed to dismiss their suit against Open Bio, and Open Bio agreed to dismiss its counterclaims. As part of the settlement, Open Bio will acquire certain licensing rights to patents covering the use of Oxford’s LentiVector technology in research activities.
Other details of the settlement were not disclosed by the firms.
The dispute began in mid-2006, when Sigma-Aldrich and Oxford sued Open Bio for allegedly infringing two US patents held by Oxford and exclusively licensed by Sigma-Aldrich. In their lawsuit, the co-plaintiffs contend that numerous Open Bio products, including its RNAi Consortium shRNA lentiviral library and its shRNAmir libraries, infringed the IP.
As reported by GenomeWeb Daily News sister publication RNAi News in late February, the firms had been negotiating a potential settlement. The US District Court overseeing the case granted the companies’ request for “a stay of the litigation in all respects, including but not limited to expert disclosures … [through] March 14, 2008, to allow settlement talks to proceed.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.